Immune checkpoint alterations and their blockade in COVID-19 patients

被引：4

作者：

Tan, Jiaxiong ^{[1
]}

Li, Yangqiu ^{[2
]}

机构：

[1] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[2] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China

来源：

BLOOD SCIENCE | 2022年 / 4卷 / 04期

关键词：

T-CELLS; PD-1; LYMPHOCYTES; SARS-COV-2; SIGNATURE;

D O I：

10.1097/BS9.0000000000000132

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronavirus disease 2019 (COVID-19) is a highly contagious disease that seriously affects people's lives. Immune dysfunction, which is characterized by abnormal expression of multiple immune checkpoint proteins (ICs) on immune cells, is associated with progression and poor prognosis for tumors and chronic infections. Immunotherapy targeting ICs has been well established in modulating immune function and improving clinical outcome for solid tumors and hematological malignancies. The role of ICs in different populations or COVID-19 stages and the impact of IC blockade remains unclear. In this review, we summarized current studies of alterations in ICs in COVID-19 to better understand immune changes and provide strategies for treating COVID-19 patients, particularly those with cancer.

引用

页码：192 / 198

页数：7

共 50 条

[1] Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Niewolik, Jacqueline
Mikuteit, Marie
Cossmann, Anne
Vahldiek, Kai
Gutzmer, Ralf
Mueller, Frank
Schroeder, Dominik
Heinemann, Stephanie
Behrens, Georg M. N.
Dopfer-Jablonka, Alexandra
Steffens, Sandra
Grimmelmann, Imke
ONCOLOGY, 2022, 100 (07) : 392 - 398
[2] At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer
Garassino, Marina Chiara
Ribas, Antoni
CANCER IMMUNOLOGY RESEARCH, 2021, 9 (03) : 261 - 264
[3] Immune checkpoint inhibitors in cancer patients with COVID-19
Pan, Yun
Tan, Jiaxiong
Li, Jinzhong
Li, Taoyuan
Li, Jieying
Cao, Yang
Yang, Liu
Lin, Xunge
Li, Minran
Liang, Xujing
OPEN LIFE SCIENCES, 2023, 18 (01):
[4] COVID-19 and immune checkpoint inhibitors
Ahmed, M. S.
Brehme, H.
Friedrich, S.
Reinhardt, L.
Blum, S.
Beissert, S.
Meier, F.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : E312 - E314
[5] Outcomes of Patients on Immune Checkpoint Inhibitors Infected with COVID-19
Minkove, S.
Sun, J.
Cui, X.
Cooper, D.
Eichacker, P.
Torabi-Parizi, P.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
[6] Immune checkpoint inhibition in the era of COVID-19
Kurzhals, J.
Terheyden, P.
Langan, E. A.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (01) : 176 - 179
[7] Management of immune checkpoint therapy for patients with cancer in the face of COVID-19
Shen, Chen
Li, Qianru
Wei, Yongchang
Li, Yuting
Li, Jun
Tao, Juan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[8] Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
Tan, Ruoding
Yun, Cindy
Seetasith, Arpamas
Sheinson, Daniel
Walls, Robert
Ngwa, Innocent
Reddy, Josina C.
Zhang, Qing
Secrest, Matthew H.
Lambert, Peter
Sarsour, Khaled
ONCOLOGIST, 2022, 27 (03): : 236 - 243
[9] IMPACT OF COVID-19 ON CANCER PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS
Tyan, Kevin
Bui, Ai-Tram
Giobbie-Hurder, Anita
Klein, Isaac
Manos, Michael
Zubiri, Leyre
Reynolds, Kerry
Grover, Shilpa
Weinhouse, Gerald
Ott, Patrick
LeBoeuf, Nicole
Rahma, Osama
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A296 - A298
[10] Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Klebanov, Nikolai
Pahalyants, Vartan
Murphy, William S.
Theodosakis, Nicholas
Zubiri, Leyre
Klevens, R. Monina
Kwatra, Shawn G.
Lilly, Evelyn
Reynolds, Kerry L.
Semenov, Yevgeniy R.
ONCOLOGIST, 2021, 26 (05): : E898 - E901

← 1 2 3 4 5 →